Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection

European Journal of Surgical Oncology

Volumn 35, Issue 3, 2009, Pages 295-301

  Shantha Kumara, H M C ^a   Kirman, I ^a   Feingold, D ^a   Cekic, V ^a   Nasar, A ^a   Arnell, T ^a   Balik, E ^a   Hoffman, A ^a   Baxter, R ^a   Conte, S ^a   Whelan, R L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Angiogenesis; Angiopoietin 2; Colorectal cancer; Granulocyte macrophage colony stimulating factor; Perioperative anti cancer therapy; sVEGFR 1

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; PLACEBO; PLASMA PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SARGRAMOSTIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADENOCARCINOMA; ANGIOPOIETIN-1; ANGIOPOIETIN-2; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59849114188     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.07.012     Document Type: Article

References (29)

1. Tagliabue E., Agresti R., Casalini P., et al. Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. Eur J Cancer 42 (2006) 1057-1061
2. Coffey J.C., Smith M.J., Wang J.H., Bouchier-Hayes D., Cotter T.G., and Redmond H.P. Cancer surgery: risks and opportunities. Bioessays 28 4 (2006) 433-437
3. Kodama M., Kodama T., Nishi Y., et al. Does Surgical Stress cause tumor metastases?. Anticancer Res 12 (1992) 1603-1616
4. Asahara T., Chen D., Takahashi T., et al. Tie2 Receptor ligands Angiopoietin-1 and Angiopoietin-2, Modulate VEGF-induced neovascularization. Circ Res 83 (1998) 233-240
5. Lee S.W., Gleason N.R., Southall J.C., et al. A serum soluble factor(s) stimulates tumor growth following laparotomy in a murine model. Surg Endosc 14 5 (2000) 490-494
6. Kirman I., Cekic V., Poltaratskaia N., et al. Plasma from patients undergoing major open surgery stimulates in vitro tumor growth; lower IGF-BP3 levels may, in part, account for this change. Surgery 132 (2002) 186-192
7. Belizon A., Balik E., Feingold D.L., et al. Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg 244 5 (2006) 792-798
8. Belizon A., Balik E., Horst P., et al. Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection. Surg Endosc 22 2 (2008) 287-297
9. Kumara S., Hoffman A., Nasar A., Belizon A., Baxter R., Jain S., Feingold D., Arnell T., Marodi D., and Whelan R.L. Colorectal resection, open more so than minimally invasive in patients with benign indications is associated with proangiogenic changes in the plasma levels of angiopoietin 1 and 2. Surg Endosc 21 (2007) S352-S482
10. Allendorf J.D., Bessler M., Horvath K.D., et al. Increased tumor establishment and growth after open versus laparoscopic surgery in mice may be related to differences in postoperative T-cell function. Surg Endosc 13 (1999) 233-235
11. Schuurman B., Heuff G., Beelen R.H., and Meyers S. Enhanced killing capacity of human Kupffer cells after activation with granulocyte/macrophage-colony-stimulating factor and interferon gamma. Cancer Immunol Immunother 39 (1994) 179-184
12. Hill A.D., Redmond H.P., Naama H.A., and Bouchier-Hayes D. Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative period. Surgery 119 (1996) 178-185
13. Eubank T.D., Roberts R., Galloway M., et al. GM-CSF induces expression of soluble VEGFR1 from human monocytes and inhibits angiogenesis in mice. Immunity 21 (2004) 831-842
14. Kirman I., Belizon A., Balik E., et al. Perioperative Sargramostim (recombinant human GM-CSF) Induces an Increase in the Level of Soluble VEGFR1 in Colon Cancer Patients Undergoing Surgery. Eur J Surg Oncol 33 10 (2007) 1169-1176
15. Holash J., Wiegand S.J., and Yancopoulos G.D. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18 (1999) 5356-5362
16. Folkman J. Addressing tumor blood vessels. Nat Biotechnol 15 (1997) 510
17. Karayiannakis A.J., Zbar A., Polychronidis A., et al. Serum and drainage fluid vascular endothelial growth factor levels in early surgical wounds. Eur Surg Res 35 6 (2003) 492-496
18. Hormbrey E., Han C., Roberts A., et al. The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin Cancer Res 9 12 (2003) 4332-4339
19. Thornton A.D., Ravn P., Winslet M., et al. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg 93 12 (2006) 1456-1463
20. Pelletier L., Regnard J., Fellman D., et al. An in vitro model for the study of human bone marrow angiogenesis: role of hematopoetic cytokines. Lab Invest 80 (2000) 501-511
21. Bussolino F., Wang J., Turrini F., et al. Stimulation of the Na/H exchanger in human endothelial cells activated by granulocyte-macrophage colony-stimulating factor. Evidence for a role in proliferation migration. J Biol Chem 264 (1989) 18284-18287
22. Valdembri D., Serini G., Vacca A., et al. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GMCSF. FASEB J 16 2 (2001) 225-227
23. Gerharz C.D., Reinecke P., Schneider E.M., Schmitz M., and Gabbert H.E. Secretion of GM-CSF and M-CSF by human renal cell carcinomas of different histologic types. Urology 58 (2001) 821-827
24. Berdel W.E.S., Danhauser-Riedl S., Steinhauser G., et al. Various human hematopoietic growth factors (Interleukin-3, GMCSF, GCSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 73 (1989) 80-83
25. Tsuruta N., Yatsunami J., Takayama K., Nakanishi Y., Ichinose Y., and Hara N. Granulocyte-macrophage-colony stimulating factor stimulates tumor invasiveness in squamous cell lung carcinoma. Cancer 82 (1998) 2173-2183
26. Ruff M.R., Farrar W.L., and Pert C.B. Interferon and granulocyte/macrophage colony stimulating factor inhibit growth and induce antigens characteristic of myleloid differentiation in small cell lung cancer cell lines. Proc Natl Acad Sci USA 83 (1986) 6613
27. Olver I.N., Hercus T., Lopez A., et al. A phase I study of the GM-CSF antagonist E21R. Cancer Chemother Pharmacol 50 (2002) 171-178
28. Correale P., Cusi M.G., Tsang K.Y., et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23 (2005) 8950-8958
29. Wu F.P.K., Westphal J.R., Hoekman K., et al. The effects of surgery, with and without rhGMCSF, on the angiogenic profile of patients treated for colorectal carcinoma. Cytokine 25 (2004) 68-72